Axim Biotechnologies has developed a rapid quantitative tear test to detect an inflammatory biomarker for dry eye disease, according to a press release.

Diagnosis and treatment of dry eye disease (DED) can be difficult because of the discordance between signs and symptoms. Inflammation may be present before clinical signs, so it may be helpful to detect the inflammatory biomarker matrix metalloproteinase-9 (MMP-9) early.

“Currently available MMP-9 testing does not detect a reduction in tear MMP-9 levels until the concentration drops below 40 ng/mL and thus may miss clinically significant improvement that did not reach that threshold,” Axim chief medical officer Joseph Tauber, MD, said in the release.